| Migraine Disorders

Zavzpret vs Zembrace SymTouch

Side-by-side clinical, coverage, and cost comparison for migraine disorders.
Deep comparison between: Zavzpret vs Zembrace Symtouch with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsZembrace Symtouch has a higher rate of injection site reactions vs Zavzpret based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zembrace Symtouch but not Zavzpret, including UnitedHealthcare
Sign up to reveal the full AI analysis
Zavzpret
Zembrace Symtouch
At A Glance
Intranasal
As needed
CGRP receptor antagonist
SC injection
As needed
5-HT1B/1D receptor agonist
Indications
  • Migraine Disorders
  • Migraine Disorders
Dosing
Migraine Disorders 10 mg as a single spray in one nostril as needed; maximum 10 mg (one spray) per 24-hour period; safety of treating more than 8 migraines in a 30-day period has not been established.
Migraine Disorders 3 mg SC injection per dose; max 12 mg per 24 hours with doses separated by at least 1 hour.
Contraindications
  • History of hypersensitivity reaction to zavegepant or any component of ZAVZPRET, including anaphylaxis
  • Ischemic coronary artery disease (CAD) (angina pectoris, history of myocardial infarction, or documented silent ischemia) or coronary artery vasospasm, including Prinzmetal's angina
  • Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders
  • History of stroke or transient ischemic attack (TIA) or history of hemiplegic or basilar migraine
  • Peripheral vascular disease
  • Ischemic bowel disease
  • Uncontrolled hypertension
  • Recent (within 24 hours) use of ergotamine-containing medication, ergot-type medication (such as dihydroergotamine or methysergide), or another 5-HT1 agonist
  • Concurrent administration of an MAO-A inhibitor or recent (within 2 weeks) use of an MAO-A inhibitor
  • Known hypersensitivity to sumatriptan (angioedema and anaphylaxis seen)
  • Severe hepatic impairment
Adverse Reactions
Most common (>=2%) Taste disorders (dysgeusia, ageusia), nausea, nasal discomfort, vomiting
Serious Hypersensitivity including facial swelling and urticaria (less than 1%)
Postmarketing Hypersensitivity (anaphylaxis), hypertension, Raynaud's phenomenon
Most common (>=2%) Injection site reactions, atypical sensations, tingling, dizziness/vertigo, warm/hot sensation, flushing, feeling of heaviness, burning sensation, pressure sensation, weakness, neck pain/stiffness
Serious Myocardial ischemia/infarction, Prinzmetal's angina, arrhythmias, chest/throat/neck/jaw pain or tightness, cerebrovascular events, vasospasm reactions, medication overuse headache, serotonin syndrome, hypertensive crisis, hypersensitivity reactions, seizures
Postmarketing Hypotension, palpitations, dystonia, tremor
Pharmacology
Zavegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist; it blocks CGRP receptor signaling implicated in migraine pathophysiology.
Sumatriptan is a selective 5-HT1B/1D receptor agonist that exerts therapeutic effects through agonist activity at receptors on intracranial blood vessels and sensory nerves of the trigeminal system, resulting in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Zavzpret
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
View full coverage details ›
Zembrace Symtouch
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
View full coverage details ›
UnitedHealthcare
Zavzpret
  • Covered on 4 commercial plans
  • PA (5/8) · Step Therapy (4/8) · Qty limit (4/8)
View full coverage details ›
Zembrace Symtouch
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
View full coverage details ›
Humana
Zavzpret
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (2/3) · Qty limit (3/3)
View full coverage details ›
Zembrace Symtouch
  • Covered on 0 commercial plans
  • PA (1/3) · Step Therapy (3/3) · Qty limit (3/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availablePAF Co-Pay Relief: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Zembrace Symtouch.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
ZavzpretView full Zavzpret profile
Zembrace SymtouchView full Zembrace Symtouch profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.